ReCode Therapeutics
Dallas
About ReCode Therapeutics
ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics. Its selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The company aims to leverage innovative technologies to provide solutions for individuals affected by genetic diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $386.4M
- Last round: Debt Financing (Sep 2025)
- Website: recodetx.com
- Phone: 469-306-1618
Industries & Categories
Biopharma, Biotechnology, Genetics, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/recode-therapeutics-1496 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.